Can-Fite BioPharma Ltd. (TLV:CANF)
Israel · Delayed Price · Currency is ILS · Price in ILA 480.00
+16.50 (3.56%)
Jun 24, 2026, 3:53 PM IDT
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
258.23K ILS
Profits / Employee
-6.27M ILS
Market Cap
19.86M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| Bonus BioGroup | 42 |
| BioLineRx | 24 |
| Matricelf | 15 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 10 |
| Geffen Residence & Renewal | 6 |
| BioLight Life Sciences | 4 |
Can-Fite BioPharma News
- 2 days ago - Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson - GlobeNewsWire
- 7 days ago - Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 - GlobeNewsWire
- 22 days ago - Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism - GlobeNewsWire
- 5 weeks ago - Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market - GlobeNewsWire
- 5 weeks ago - Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital - TheFly
- 6 weeks ago - Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy - GlobeNewsWire
- 6 weeks ago - Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright - TheFly
- 7 weeks ago - Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months - GlobeNewsWire